Ravi Sahu | Pharmacology | Best Researcher Award

Published on | Ravi Sahu by World Top Scientists

Best Researcher Award

Ravi Sahu – Wright State University Boonshoft School of Medicine

Ravi Sahu
Affiliation Wright State University Boonshoft School of Medicine
Country United States
Scopus ID 36833607800
Documents 1076
Citations 1372
h-index 23
Subject Area Pharmacology
Event World Top Scientist Awards
ORCID 0000-0003-3857-9073

Ravi Sahu is a pharmacology researcher associated with Wright State University Boonshoft School of Medicine in the United States. His research profile demonstrates a consistent contribution to biomedical sciences, particularly in cancer pharmacology and molecular therapeutics. The recognition under the Best Researcher Award category reflects scholarly output, citation impact, and involvement in global research collaborations. His work has contributed to advancing understanding in cancer biology, immunotherapy, and drug repurposing strategies [1].

Abstract

This article presents an academic overview of Ravi Sahu, emphasizing his scholarly contributions in pharmacology and cancer research. His work spans experimental therapeutics, immunological pathways, and drug repurposing strategies. The evaluation is based on bibliometric indicators including citation count, h-index, and research output. The profile aligns with international standards used in academic recognition systems [2].

Keywords

Pharmacology, Cancer Research, Immunotherapy, Drug Repurposing, Molecular Biology, Oncology, Research Metrics.

Introduction

The field of pharmacology has evolved significantly with the integration of molecular biology and translational medicine. Researchers such as Ravi Sahu have contributed to bridging laboratory findings with clinical applications. His research focuses on understanding cellular signaling pathways and developing therapeutic interventions. These efforts contribute to improved treatment strategies in oncology [3].

Research Profile

The research profile of Ravi Sahu indicates substantial scholarly output with over a thousand indexed documents and a growing citation base. His work is indexed in major academic databases including Scopus and ORCID. The profile reflects interdisciplinary collaboration and sustained research productivity. These indicators are commonly used to assess academic performance globally [1].

Research Contributions

Ravi Sahu has contributed to multiple areas including cancer therapeutics, platelet-activating factor signaling, and immune checkpoint research. His publications explore mechanisms of tumor progression and therapeutic resistance. The research also includes investigations into repurposed drugs such as metformin and itraconazole. These contributions enhance understanding of treatment optimization strategies [4].

Publications

The publication record includes peer-reviewed journal articles across high-impact biomedical journals. Notable works include studies on lung cancer therapies, melanoma treatment, and molecular signaling pathways. The research demonstrates both experimental and review-based scholarship. These publications contribute to advancing scientific knowledge and clinical practices [5].

Research Impact

The research impact of Ravi Sahu is reflected through citation metrics and academic collaborations. His work has been cited in multiple interdisciplinary studies, indicating relevance across scientific domains. The h-index value highlights consistent scholarly influence. Such metrics are critical in evaluating research visibility and academic significance [2].

Award Suitability

The Best Researcher Award recognizes individuals demonstrating excellence in scientific research and innovation. Ravi Sahu’s academic record meets key criteria including publication output, citation impact, and subject expertise. His involvement in international research initiatives further strengthens his eligibility. These factors collectively support recognition at global scientific platforms [3].

Conclusion

Ravi Sahu’s contributions to pharmacology and cancer research demonstrate sustained academic excellence. His work integrates molecular insights with therapeutic applications, contributing to advancements in biomedical science. The recognition under the Best Researcher Award highlights the significance of his scholarly achievements. Continued research efforts are expected to further enhance his impact in the scientific community [4].

References

  1. Elsevier. (n.d.). Scopus author details: Ravi Sahu, Author ID 36833607800. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=36833607800

  2. Sahu, R. P., Zonfa, C. E., & Thyagarajan, A. (2026). Repurposing itraconazole in combination with chemotherapy and immune checkpoint inhibitor for cancer. Medical Sciences, 14(1), 55.
    https://doi.org/10.3390/medsci14010055

  3. Thyagarajan, A., Gajjar, V., & Sahu, R. P. (2025). Are metformin-based combination approaches beneficial for non-small cell lung cancer: Evidence from experimental and clinical studies. Military Medical Research, 12, 61.
    https://doi.org/10.1186/s40779-025-00649-5

  4. Sahu, R. P., et al. (2025). Platelet-activating factor signaling in cancer. Journal of Applied Toxicology. Advance online publication. https://doi.org/10.1002/jat.4770

  5. Sahu, R. P., et al. (2023). Melatonin in melanoma treatment. Medical Sciences, 11(1), 9.

    https://doi.org/10.3390/medsci11010009

     

Meghraj Suryawanshi | Pharmacology and Pharmaceutical Science | Best Researcher Award

Published on | Meghraj Suryawanshi by World Top Scientists

Prof. Dr. Meghraj Suryawanshi | Pharmacology and Pharmaceutical Science | Best Researcher Award

Assistant Professor | Sandip Institute of Pharmaceutical Sciences | India

Dr. Meghraj Vivekanand Suryawanshi is an accomplished Associate Professor and Training & Placement Coordinator at the Sandip Institute of Pharmaceutical Sciences, Nashik, specializing in pharmaceutics. He holds a Ph.D. in Pharmaceutics from Jaipur National University, an M.Pharm in Pharmaceutics from R.C. Patel Institute of Pharmaceutical Education and Research, a B.Pharm from Sinhgad Institutes of Pharmaceutical Sciences, and an MBA in Hospital Administration. Dr. Suryawanshi has extensive professional experience, serving as a Ph.D. research scholar, Assistant Professor at multiple institutions, and co-founder and CTO of AllWell Nutritech LLP, where he contributed to start-up incubation and entrepreneurial initiatives. He has supervised numerous undergraduate and postgraduate students and actively coordinated academic and administrative programs including training and placement, entrepreneurship, library management, and examination coordination. His research focuses on advanced drug delivery systems, formulation development, and pharmaceutical technology, with a significant body of publications contributing to national and international journals. Dr. Suryawanshi has also engaged in editorial responsibilities and professional memberships that support scholarly exchange and innovation in the pharmaceutical sciences. Recognized for his dedication to research, education, and mentorship, he has been instrumental in fostering academic excellence, student development, and industry collaboration, demonstrating leadership, scientific rigor, and a commitment to advancing the field of pharmaceutics at both institutional and broader professional levels.

Profiles: Google Scholar | Scopus | ORCID

Featured Publications

1. Suryawanshi, I., Srinidhi, S., Singh, S., Kalia, R., Kunchala, R. K., Mudavath, S. L., …. (2021). Downshifting and upconversion dual mode emission from lanthanide doped GdPO4 nanorods for unclonable anti-counterfeiting. Materials Today Communications, 26, 102144.

2. Patil, S. M., Suryawanshi, M. V., Chandanshive, V. V., Kurade, M. B., Govindwar, S. P., …. (2020). Regeneration of textile wastewater deteriorated microbial diversity of soil microcosm through bioaugmentation. Chemical Engineering Journal, 380, 122533.

3. Suryawanshi, M. V., Gujarathi, P. P., Mulla, T., & Bagban, I. (2024). Hypericum perforatum: A comprehensive review on pharmacognosy, preclinical studies, putative molecular mechanism, and clinical studies in neurodegenerative disorders. Naunyn-Schmiedeberg’s Archives of Pharmacology, 397(6), 3803–3818.

4. Bhagat, D. S., Suryawanshi, I. V., Gurnule, W. B., Sawant, S. S., & Chavan, P. B. (2021). Greener synthesis of CuO nanoparticles for enhanced development of latent fingerprints. Materials Today: Proceedings, 36, 747–750.

5. Suryawanshi, I., Kalia, R., Kunchala, R. K., Mudavath, S. L., & Naidu, B. S. (2022). Detection of latent fingerprints using luminescent Gd0.95Eu0.05PO4 nanorods. Journal of Rare Earths, 40(4), 572–578.

Lixin Yan | Pharmacology | Best Researcher Award

Published on | Lixin Yan by World Top Scientists

Mrs. Lixin Yan | Pharmacology | Best Researcher Award

Medical manager | Sinocelltech Ltd | China

Mrs. Lixin Yan is an accomplished medical manager with extensive experience in clinical research, specializing in oncology, infectious diseases, vaccines, and metabolic products. Over the years, she has led multiple Phase I–III clinical trials, contributing to protocol development, medical monitoring, feasibility assessment, and regulatory submissions. Her work has been instrumental in the clinical development of innovative therapies, including PD-1 inhibitors, EGFR-targeted treatments, HPV and COVID-19 vaccines, insulin, and GLP-1 products. She demonstrates strong expertise in GCP compliance, regulatory processes, and cross-functional team collaboration, ensuring high-quality research outcomes. Mrs. Yan has published impactful peer-reviewed articles, including first-author papers, highlighting her ability to generate reliable clinical evidence. Her dedication to advancing medical science through rigorous research and mentorship reflects her potential to lead future high-impact studies. Her measurable research impact is demonstrated through 68 citations, 5 documents, and an h-index of 4 according to Scopus.

Profile: Scopus

Featured Publications

1. L. Yan, J. Yi, D. Liu, J. Li, A. A. H. Baidoo, and L. Xie, “Efficacy and safety of SARS-CoV-2 neutralizing antibody, SCTA01, in high-risk outpatients diagnosed with COVID-19: A Phase II clinical trial,” Contemporary Clinical Trials Communications, 2025.

Nceba Gqaleni | Pharmacology, Toxicology and Pharmaceutical Science | Best Researcher Award

Published on | Nceba Gqaleni by World Top Scientists

Prof. Nceba Gqaleni | Pharmacology, Toxicology and Pharmaceutical Science | Best Researcher Award

Research Professor at University of KwaZulu-Natal, South Africa

Professor Nceba Gqaleni is a renowned academic and researcher at the University of KwaZulu-Natal, South Africa. He currently serves as an Acting Academic Leader in the Discipline of Traditional Medicine and as a Research Professor. With a passion for integrating traditional medicine into mainstream healthcare, his research aims to address health challenges facing Africa, including HIV, diabetes, and cancer. His work on herbal treatments and immunomodulators has positioned him as a pioneer in exploring alternative therapies. Prof. Gqaleni’s research is characterized by the synergy between modern science and indigenous knowledge systems, contributing significantly to the global healthcare landscape. His work continues to impact public health, with ongoing clinical trials and innovative studies aimed at improving health outcomes. Additionally, he is committed to training the next generation of researchers, having mentored numerous postdoctoral, PhD, and master’s students.

Professional Profile

Education

Professor Nceba Gqaleni’s educational background is rooted in biochemistry, with a PhD in Biochemistry from the University of Strathclyde in Glasgow, UK. He also holds a Master’s degree in Biochemistry from the University of KwaZulu-Natal (UKZN), South Africa. His academic journey has been marked by a deep interest in both the molecular and traditional aspects of medicine, leading him to pursue research that bridges these fields. His formal education laid the foundation for a distinguished career in both academia and research, where he has applied his scientific expertise to explore alternative therapies and the integration of traditional medicine into contemporary health systems. Prof. Gqaleni’s educational path reflects a commitment to advancing knowledge and improving healthcare, particularly in the African context.

Professional Experience

Professor Gqaleni’s professional experience spans academia, research, and leadership. He currently holds the position of Acting Academic Leader in the Discipline of Traditional Medicine at the University of KwaZulu-Natal. His role involves guiding academic initiatives and research in traditional medicine, while also providing leadership in curriculum development and research supervision. In addition to his academic responsibilities, Prof. Gqaleni has led numerous significant research projects, particularly focused on traditional medicine’s role in addressing major health issues such as HIV and diabetes. His extensive work in supervising postgraduate students, including over 7 postdoctoral researchers, 12 PhD candidates, and 25 master’s students, demonstrates his dedication to nurturing the next generation of scholars and researchers. Prof. Gqaleni’s professional experience is a blend of academic excellence, mentorship, and groundbreaking research in the field of traditional medicine and biochemistry.

Research Interests

Professor Nceba Gqaleni’s research interests lie at the intersection of biochemistry and traditional medicine, with a primary focus on finding alternative treatments for diseases prevalent in Africa, such as HIV, diabetes, and cancer. He has led pioneering research on herbal compositions for the treatment of HIV and is currently conducting clinical trials for a patented HIV cure. In addition to HIV, his research extends to cancer therapies, immunomodulators, and the application of Indigenous phytotherapy in managing diseases like diabetes and HIV. Prof. Gqaleni’s ongoing research projects also explore the health and wellness of Indigenous peoples, particularly in the context of climate change and global health disparities. His work is driven by the goal of bridging the gap between traditional healing practices and modern medical approaches, thereby improving health outcomes in African communities and globally.

Awards and Honors

Professor Nceba Gqaleni’s career has been marked by significant achievements and recognition. He has been honored for his pioneering work in traditional medicine and biochemistry, particularly in the field of HIV and diabetes treatment. One of his notable accomplishments is the filing of a patent for a herbal composition aimed at curing HIV, which is currently undergoing clinical trials. Prof. Gqaleni has also received substantial funding for his research, including a $4.4 million NIH grant for a study on Indigenous phytotherapy. His contributions to science and public health have earned him the respect of both academic and medical communities. Prof. Gqaleni’s work in advancing the integration of traditional medicine into global health systems continues to garner international attention and recognition. His awards and honors reflect his exceptional leadership and groundbreaking contributions to healthcare research.

Conclusion

Professor Nceba Gqaleni demonstrates exceptional potential for the Best Researcher Award due to his innovative contributions to HIV treatment, integration of traditional medicine, and impactful mentorship. His work addresses critical health challenges in Africa, blending traditional knowledge with modern scientific methods. While broader dissemination and commercialization efforts could strengthen his profile, his contributions make him a strong contender for the award.

Publications Top Noted

  • Indigenous Medicinal Plants Used in the Management of Diabetes in Africa: 5 Years (2019–2024) in Perspective
    • Authors: Frimpong, E.K., Thembane, N., Hlatshwayo, S., Ngcobo, M., Gqaleni, N.
    • Year: 2024
    • Citations: 2
  • Review on the Anti-Hyperglycemic Potential of Psidium guajava and Seriphium plumosum L.
    • Authors: Thembane, N., Hlatshwayo, S., Ngcobo, M., Ngubane, P., Gqaleni, N.
    • Year: 2024
    • Citations: 1
  • Erratum: An in vitro study to elucidate the effects of Product Nkabinde on immune response in peripheral blood mononuclear cells of healthy donors
    • Authors: Setlhare, B., Letsoalo, M., Nkabinde, S.A., Ngcobo, M., Gqaleni, N.
    • Year: 2024
    • Citations: 0
  • An in vitro study to elucidate the effects of product Nkabinde on immune response in peripheral blood mononuclear cells of healthy donors
    • Authors: Setlhare, B., Letsoalo, M., Nkabinde, S.A., Ngcobo, M., Gqaleni, N.
    • Year: 2024
    • Citations: 1
  • Analysis of Three Species of Cassipourea Traditionally Used for Hypermelanosis in Selected Provinces in South Africa
    • Authors: Mpofana, N., Yalo, M., Gqaleni, N., Dlova, N.C., Hussein, A.A.
    • Year: 2024
    • Citations: 0
  • Melasma in People with Darker Skin Types: A Scoping Review Protocol on Prevalence, Treatment Options for Melasma, and Impact on Quality of Life
    • Authors: Mpofana, N., Chibi, B., Gqaleni, N., Kgarosi, K., Dlova, N.C.
    • Year: 2023
    • Citations: 3
  • The Effect of Melasma on the Quality of Life in People with Darker Skin Types Living in Durban, South Africa
    • Authors: Mpofana, N., Paulse, M., Gqaleni, N., Hussein, A., Dlova, N.C.
    • Year: 2023
    • Citations: 0
  • The Met and Unmet Health Needs for HIV, Hypertension, and Diabetes in Rural KwaZulu-Natal, South Africa: Analysis of a Cross-Sectional Multimorbidity Survey
    • Authors: Singh, U., Olivier, S., Cuadros, D., Ramnanan, A., Harilall, S., Gqaleni, N.
    • Year: 2023
    • Citations: 5
  • An Investigation into the Acute and Subacute Toxicity of Extracts of Cassipourea flanaganii Stem Bark In Vivo
    • Authors: Mpofana, N., Chipangura, J.K., Paulse, M., Hussein, A.A., Crouch, N.R.
    • Year: 2023
    • Citations: 2
  • Treatment of Melasma on Darker Skin Types: A Scoping Review
    • Authors: Mpofana, N., Chibi, B., Visser, T., Hussein, A.A., Dlova, N.C.
    • Year: 2023
    • Citations: 4